Drug Profile
Oritavancin - Melinta Therapeutics
Alternative Names: KIMYRSA; LY-333328; LY-333328 diphosphate; Nuvocid; ORBACTIV; Oritavancin diphosphate; RamvocidLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Melinta Therapeutics; Menarini; The Medicines Company
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Skin and soft tissue infections
- Phase II Bacteraemia
- No development reported Gram-positive infections
- Discontinued Anthrax; Clostridium difficile infections
Most Recent Events
- 15 May 2023 Oritavancin licensed to Xediton Pharmaceuticals in Canada
- 13 Apr 2023 Phase-II clinical trials in Skin and soft tissue infections (In adolescents, In children, In infants) in Spain, Bulgaria (IV) (EudraCT2022-001297-63)
- 31 Oct 2022 Melinta Therapeutics plans a phase II trial for Skin and soft tissue infections (In infants, In children, In adolescents) in USA (IV, Infusion, Single) in October 2022 (NCT05599295) (EudraCT2022-001297-63)